Current approaches to childhood nephrotic syndrome (NS) are based on routine clinical and laboratory findings that are unable to accurately define the underlying biologic mechanisms, predict clinical course, or select optimal therapy. Treatment of childhood NS lacks a rational mechanistic basis and is associated with significant morbidity and is responsible for 12% of the pediatric end stage kidney disease in the USA. A precision medicine approach is warranted to identify mechanistically discrete disease subgroups, refine biomarkers to assist with molecular classification, identify relevant treatment targets, and improve trial design for pediatric NS. The children's nephrotic syndrome cohort in the Nephrotic Syndrome Study Network (Cohort B) is inclusive of 16 enrolling pediatric centers and associated investigators. In this project, Cohort B will expand to 200 children with incident NS, prospectively followed to define the longitudinal disease course, collect biospecimens to enable comprehensive molecular profiling (phenotype, genotype, immune profiling) for treatment target identification. cNEPTUNE will develop and improve clinical trial methods, endpoints, and systems to enable the conduct of precision medicine trials inclusive of children with nephrotic syndrome. In this renewal proposal, we propose to (a) define genotype-phenotype subgroups of children with incident NS; (b) define non-invasive biomarkers, inclusive of immunological profiles, in functionally defined subgroups of NS; (c) identify candidate therapeutic targets based on the mechanistically defined NS; and (d) develop validated endpoints, trial designs, and systems to foster efficient and effective precision medicine clinical trials for patients with NS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54DK083912-11
Application #
9804076
Study Section
Special Emphasis Panel (ZTR1)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Park, Sun-Ji; Kim, Yeawon; Chen, Ying Maggie (2018) Endoplasmic reticulum stress and monogenic kidney diseases in precision nephrology. Pediatr Nephrol :
Miyata, Kana N; Nast, Cynthia C; Dai, Tiane et al. (2018) Renal matrix Gla protein expression increases progressively with CKD and predicts renal outcome. Exp Mol Pathol 105:120-129
Grayson, Peter C; Eddy, Sean; Taroni, Jaclyn N et al. (2018) Metabolic pathways and immunometabolism in rare kidney diseases. Ann Rheum Dis 77:1226-1233
Czerniecki, Stefan M; Cruz, Nelly M; Harder, Jennifer L et al. (2018) High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping. Cell Stem Cell 22:929-940.e4
Zee, Jarcy; Hodgin, Jeffrey B; Mariani, Laura H et al. (2018) Reproducibility and Feasibility of Strategies for Morphologic Assessment of Renal Biopsies Using the Nephrotic Syndrome Study Network Digital Pathology Scoring System. Arch Pathol Lab Med 142:613-625
Mariani, Laura H; Martini, Sebastian; Barisoni, Laura et al. (2018) Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. Nephrol Dial Transplant 33:310-318
Mitrofanova, Alla; Molina, Judith; Varona Santos, Javier et al. (2018) Hydroxypropyl-?-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney Int 94:1151-1159
Troost, Jonathan P; Trachtman, Howard; Nachman, Patrick H et al. (2018) An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 13:414-421
Nair, Viji; Komorowsky, Claudiu V; Weil, E Jennifer et al. (2018) A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. Kidney Int 93:439-449
Zhong, Fang; Chen, Zhaohong; Zhang, Liwen et al. (2018) Tyro3 is a podocyte protective factor in glomerular disease. JCI Insight 3:

Showing the most recent 10 out of 76 publications